Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses

Journal of Virology

Volumn 79, Issue 20, 2005, Pages 12807-12817

  Báez Astúa, Andrés ^a   Herráez Hernández, Elsa ^a   Garbi, Natalio ^b   Pasolli, Hilda A ^c   Juárez, Victoria ^d   Zur Hausen, Harald ^b   Cid Arregui, Angel ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c ROCKEFELLER UNIVERSITY   (United States)

^d EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HEPATITIS B SURFACE ANTIGEN; PROTEIN E7; RECOMBINANT HEPATITIS B VACCINE; VIRUS VACCINE;

ADENOVIRUS; ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; VIRUS PARTICLE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CANCER VACCINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GENETIC VECTORS; HEPATITIS B SURFACE ANTIGENS; IMMUNIZATION; LYMPH NODES; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; SPECIES SPECIFICITY; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VACCINES, SYNTHETIC; VIRAL VACCINES;

ADENOVIRIDAE; HEPATITIS B VIRUS; HUMAN ADENOVIRUS TYPE 5; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRUS;

EID: 26444607877     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.20.12807-12817.2005     Document Type: Article

References (46)

1. Aichele, P., K. Brduscha-Riem, S. Oehen, B. Odermatt, R. M. Zinkernagel, H. Hengartner, and H. Pircher. 1997. Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity 6:519-529.
2. Bontkes, H. J., T. D. de Gruijl, A. J. van den Muysenberg, R. H. Verheijen, M. J. Stukart, C. J. Meijer, R. J. Scheper, S. N. Stacey, M. F. Duggan Keen, P. L. Stern, S. Man, L. K. Borysiewicz, and J. M. Walboomers. 2000. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int. J. Cancer. 88:92-98.
3. Bruss, V., and D. Ganem. 1991. Mutational analysis of hepatitis B surface antigen particle assembly and secretion. J. Virol. 65:3813-3820.
4. Cid-Arregui, A., V. Juarez, and H. zur Hausen. 2003. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J. Virol. 77:4928-4937.
5. Davidson, E. J., R. L. Faulkner, P. Sehr, M. Pawlita, L. J. Smyth, D. J. Burt, A. E. Tomlinson, J. Hickling, H. C. Kitchener, and P. L. Stern. 2004. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 22:2722-2729.
6. Davis, H. L., M. L. Michel, and R. G. Whalen. 1993. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. 2:1847-1851.
7. Delpeyroux, F., N. Chenciner, A. Lim, M. Lambert, Y. Malpiece, and R. E. Streeck. 1987. Insertions in the hepatitis B surface antigen. Effect on assembly and secretion of 22-nm particles from mammalian cells. J. Mol. Biol. 195:343-350.
8. Delpeyroux, F., N. Chenciner, A. Lim, Y. Malpiece, B. Blondel, R. Crainic, S. van der Werf, and R. E. Streeck. 1986. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science 233:472-475.
9. Delpeyroux, F., E. Van Wezel, B. Blondel, and R. Crainic. 1990. Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles. J. Virol. 64:6090-6100.
10. Dermime, S., D. E. Gilham, D. M. Shaw, E. J. Davidson, K. Meziane el, A. Armstrong, R. E. Hawkins, and P. L. Stern. 2004. Vaccine and antibody-directed T cell tumour immunotherapy. Biochim. Biophys. Acta 1704:11-35.
11. Dubois, M. F., C. Pourcel, S. Rousset, C. Chany, and P. Tiollais. 1980. Excretion of hepatitis B surface antigen particles from mouse cells transformed with cloned viral DNA. Proc. Natl. Acad. Sci. USA 77:4549-4553.
12. Evander, M., K. Edlund, A. Gustafsson, M. Jonsson, R. Karlsson, E. Rylander, and G. Wadell. 1995. Human papillomavirus infection is transient in young women: a population-based cohort study. J. Infect. Dis. 171:1026-1030.
13. Feuerer, M., P. Beckhove, N. Garbi, Y. Mahnke, A. Limmer, M. Hommel, G. J. Hammerling, B. Kyewski, A. Hamann, V. Umansky, and V. Schirrmacher. 2003. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat. Med. 9:1151-1157. (First published 10 August 2003; 10.1038/nm914.)
14. Frazer, I. H., M. Quinn, J. L. Nicklin, J. Tan, L. C. Perrin, P. Ng, V. M. O'Connor, O. White, N. Wendt, J. Martin, J. M. Crowley, S. J. Edwards, A. W. McKenzie, S. V. Mitchell, D. W. Maher, M. J. Pearse, and R. L. Basser. 2004. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23:172-181.
15. Ganem, D. 1996. Hepadnaviridae and their replication, p. 1199-1233. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fundamental virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
16. Hallez, S., P. Simon, F. Maudoux, J. Doyen, J. C. Noel, A. Beliard, X. Capelle, F. Buxant, I. Fayt, A. C. Lagrost, P. Hubert, C. Gerday, A. Burny, J. Boniver, J. M. Foidart, P. Delvenne, and N. Jacobs. 2004. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol. Immunother. 53:642-650.
17. He, X. S., H. S. Chen, K. Chu, M. Rivkina, and W. S. Robinson. 1996. Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen. Proc. Natl. Acad. Sci. USA 93:7274-7278.
18. Ho, G. Y., R. Bierman, L. Beardsley, C. J. Chang, and R. D. Burk. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338:423-428.
19. Hui, J., M. Mancini, G. Li, Y. Wang, P. Tiollais, and M. L. Michel. 1999. Immunization with a plasmid encoding a modified hepatitis B surface antigen carrying the receptor binding site for hepatocytes. Vaccine 17:1711-1718.
20. Jochmus, I., W. Osen, A. Altmann, G. Buck, B. Hofmann, A. Schneider, L. Gissmann, and H. G. Rammensee. 1997. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. J. Gen. Virol. 78:1689-1695.
21. Kadish, A. S., G. Y. Ho, R. D. Burk, Y. Wang, S. L. Romney, R. Ledwidge, and R. H. Angeletti. 1997. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J. Natl. Cancer Inst. 89:1285-1293.
22. Koutsky, L. A., K. A. Ault, C. M. Wheeler, D. R. Brown, E. Barr, F. B. Alvarez, L. M. Chiacchierini, K. and U. Jansen. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-1651.
23. Kowalczyk, D. W., A. P. Wlazlo, S. Shane, and H. C. Ertl. 2001. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. Vaccine 19:3583-3590.
24. Lee, I. H., C. H. Kim, and W. S. Ryu. 1996. Presentation of the hydrophilic domains of hepatitis C viral E2 envelope glycoprotein on hepatitis B surface antigen particles. J. Med. Virol. 50:145-151.
25. Lichtenstein, D. L., and W. S. Wold. 2004. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. 11:819-829.
26. Liu, C. C., D. Yansura, and A. D. Levinson. 1982. Direct expression of hepatitis B surface antigen in monkey cells from an SV40 vector. DNA 1:213-221.
27. Liu, M., B. Acres, J. M. Balloul, N. Bizouarne, S. Paul, P. Slos, and P. Squiban. 2004. Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. USA 101(Suppl. 2):14567-14571.
28. Michel, M. L., H. L. Davis, M. Schleef, M. Mancini, P. Tiollais, and R. G. Whalen. 1995. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc. Natl. Acad. Sci. USA 92:5307-5311.
29. Michel, M. L., M. Mancini, E. Sobczak, V. Favier, D. Guetard, E. M. Bahraoui, and P. Tiollais. 1988. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen particles. Proc. Natl. Acad. Sci. USA 85:7957-7961.
30. Netter, H. J., T. B. Macnaughton, W. P. Woo, R. Tindle, and E. J. Gowans. 2001. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J. Virol. 75:2130-2141.
31. Ressing, M. E., W. J. van Driel, E. Celis, A. Sette, M. P. Brandt, M. Hartman, J. D. Anholts, G. M. Schreuder, W. B. ter Harmsel, G. J. Fleuren, B. J. Trimbos, W. M. Kast, and C. J. Melief. 1996. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res. 56:582-588.
32. Rogoff, H. A., M. T. Pickering, F. M. Frame, M. E. Debatis, Y. Sanchez, S. Jones, and T. F. Kowalik. 2004. Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol. Cell. Biol. 24:2968-2977.
33. Schirmbeck, R., K. Melber, T. Mertens, and J. Reimann. 1994. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J. Virol. 68:1418-1425.
34. Schirmbeck, R., D. Stober, S. El Kholy, P. Riedl, and J. Reimann. 2002. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes. J. Immunol. 168:6253-6262.
35. Schirmbeck, R., J. Wild, and J. Reimann. 1998. Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Eur. J. Immunol. 28:4149-4161.
36. Smyth, L. J., M. I. Van Poelgeest, E. J. Davidson, K. M. Kwappenberg, D. Burt, P. Sehr, M. Pawlita, S. Man, J. K. Hickling, A. N. Fiander, A. Tristram, H. C. Kitchener, R. Offringa, P. L. Stern, and S. H. Van Der Burg. 2004. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin. Cancer Res 10:2954-2961.
37. Sonnhammer, E. L. L., G. von Heijne, and A. Krogh. 1998. A hidden Markov model for predicting transmembrane helices in protein sequences, p. pp175-182. In J. Glasgow, T. Litteljohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen (ed.), Proceedings of the 6th International Conference on Intelligent Systems for Molecular Biology. AAAI Press, MenloPark, Calif.
38. Sullivan, N. J., T. W. Geisbert, J. B. Geisbert, L. Xu, Z. Y. Yang, M. Roederer, R. A. Koup, P. B. Jahrling, and G. J. Nabel. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-684.
39. Tindle, R. W. 2002. Immune evasion in human papillomavirus-associated cervical cancer. Nat. Rev. Cancer 2:59-65.
40. Villa, L. L., R. L. Costa, C. A. Petta, R. P. Andrade, K. A. Ault, A. R. Giuliano, C. M. Wheeler, L. A. Koutsky, C. Malm, M. Lehtinen, F. E. Skjeldestad, S. E. Olsson, M. Steinwall, D. R. Brown, R. J. Kurman, B. M. Ronnett, M. H. Stoler, A. Ferenczy, D. M. Harper, G. M. Tamms, J. Yu, L. Lupinacci, R. Railkar, F. J. Taddeo, K. U. Jansen, M. T. Esser, H. L. Sings, A. J. Saah, and E. Barr. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271-278.
41. von Brunn, A., K. Fruh, H. M. Muller, H. W. Zentgraf, and H. Bujard. 1991. Epitopes of the human malaria parasite P. falciparum carried on the surface of HBsAg particles elicit an immune response against the parasite. Vaccine 9:477-484.
42. Xiang, Z. Q., G. P. Gao, A. Reyes-Sandoval, Y. Li, J. M. Wilson, and H. C. Ertl. 2003. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol. 77:10780-10789.
43. zur Hausen, H. 1999. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin. Cancer Biol. 9:405-411.
44. zur Hausen, H. 1996. Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta 1288:F55-78.
45. zur Hausen, H. 1991. Viruses in human cancers. Science 254:1167-1173.
46. Zwaveling, S., S. C. Ferreira Mota, J. Nouta, M. Johnson, G. B. Lipford, R. Offringa, S. H. van der Burg, and C. J. Melief. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169:350-358.